Ontology highlight
ABSTRACT: Purpose
Effective targeted therapies are lacking for refractory and relapsed T-cell acute lymphoblastic leukemia (T-ALL). Suppression of the NOTCH pathway using gamma-secretase inhibitors (GSI) is toxic and clinically not effective. The goal of this study was to identify alternative therapeutic strategies for T-ALL.Experimental design
We performed a comprehensive analysis of our high-throughput drug screen across hundreds of human cell lines including 15 T-ALL models. We validated and further studied the top hit, navitoclax (ABT-263). We used multiple human T-ALL cell lines as well as primary patient samples, and performed both in vitro experiments and in vivo studies on patient-derived xenograft models.Results
We found that T-ALL are hypersensitive to
SUBMITTER: Dastur A
PROVIDER: S-EPMC6320296 | biostudies-literature | 2019 Jan
REPOSITORIES: biostudies-literature